Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Wakelee on BIRCH Trial for Atezolizumab in Patients With NSCLC

Heather A. Wakelee, MD
Published: Saturday, Sep 24, 2016


Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses updated efficacy findings from the BIRCH trial, which was a phase II study of atezolizumab (Tecentriq) for patients with PD-L1–selected advanced non–small cell lung cancer (NSCLC). Wakelee discussed these findings during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

The updated results of the BIRCH study demonstrate a median overall survival of 12 months. In the first-line cohort all comers with an immunohistochemistry score of TC1/2/3 had a median survival of over 20 months. In patients who had higher PD-L1 expression, the median survival has not yet been reached, Wakelee explains.

Additional studies are exploring atezolizumab in other settings and in combination. The IMpower-110 trial is a randomized study in selected patients looking at atezolizumab compared with chemotherapy in the first-line setting, she says. The OAK study is a randomized phase III trial comparing atezolizumab with docetaxel in unselected patients in the second-line setting.

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses updated efficacy findings from the BIRCH trial, which was a phase II study of atezolizumab (Tecentriq) for patients with PD-L1–selected advanced non–small cell lung cancer (NSCLC). Wakelee discussed these findings during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

The updated results of the BIRCH study demonstrate a median overall survival of 12 months. In the first-line cohort all comers with an immunohistochemistry score of TC1/2/3 had a median survival of over 20 months. In patients who had higher PD-L1 expression, the median survival has not yet been reached, Wakelee explains.

Additional studies are exploring atezolizumab in other settings and in combination. The IMpower-110 trial is a randomized study in selected patients looking at atezolizumab compared with chemotherapy in the first-line setting, she says. The OAK study is a randomized phase III trial comparing atezolizumab with docetaxel in unselected patients in the second-line setting.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x